Compare FCNCO & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCNCO | CADL |
|---|---|---|
| Founded | 1898 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.0B |
| IPO Year | 1995 | 2021 |
| Metric | FCNCO | CADL |
|---|---|---|
| Price | $18.82 | $10.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $21.75 |
| AVG Volume (30 Days) | 20.2K | ★ 979.5K |
| Earning Date | 10-23-2025 | 11-12-2026 |
| Dividend Yield | ★ 6.17% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ 97.95 | N/A |
| Revenue | ★ $9,541,000,000.00 | $125,000.00 |
| Revenue This Year | $0.56 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $0.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.07 | $4.35 |
| 52 Week High | $23.43 | $14.00 |
| Indicator | FCNCO | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 21.26 | 40.32 |
| Support Level | N/A | $9.40 |
| Resistance Level | $20.91 | $10.59 |
| Average True Range (ATR) | 0.34 | 0.67 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 1.44 | 7.71 |
First Citizens is a US regional bank with total assets of around $237 billion as of June 30, 2026. Headquartered in Raleigh, North Carolina, First Citizens' largest markets are North Carolina, South Carolina, and California. The bank has a track record of acquiring troubled banks from the FDIC, such as Silicon Valley Bridge Bank in 2023, which doubled its asset base. First Citizens offers products and services across retail, commercial, wealth management, and railcar leasing. In 2025, First Citizens derived over 95% of its earnings from banking and less than 5% from railcar leasing.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.